Tags

Type your tag names separated by a space and hit enter

Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
Lancet Neurol. 2010 Nov; 9(11):1106-17.LN

Abstract

Levodopa is the most effective drug for the treatment of Parkinson's disease. However, the long-term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias. Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa-induced dyskinesias, their pathogenesis is still unclear. In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements. Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.

Authors+Show Affiliations

Clinica Neurologica, Università degli Studi di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy. calabre@unipg.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

20880751

Citation

Calabresi, Paolo, et al. "Levodopa-induced Dyskinesias in Patients With Parkinson's Disease: Filling the Bench-to-bedside Gap." The Lancet. Neurology, vol. 9, no. 11, 2010, pp. 1106-17.
Calabresi P, Di Filippo M, Ghiglieri V, et al. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 2010;9(11):1106-17.
Calabresi, P., Di Filippo, M., Ghiglieri, V., Tambasco, N., & Picconi, B. (2010). Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. The Lancet. Neurology, 9(11), 1106-17. https://doi.org/10.1016/S1474-4422(10)70218-0
Calabresi P, et al. Levodopa-induced Dyskinesias in Patients With Parkinson's Disease: Filling the Bench-to-bedside Gap. Lancet Neurol. 2010;9(11):1106-17. PubMed PMID: 20880751.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. AU - Calabresi,Paolo, AU - Di Filippo,Massimiliano, AU - Ghiglieri,Veronica, AU - Tambasco,Nicola, AU - Picconi,Barbara, Y1 - 2010/09/27/ PY - 2010/10/1/entrez PY - 2010/10/1/pubmed PY - 2010/11/17/medline SP - 1106 EP - 17 JF - The Lancet. Neurology JO - Lancet Neurol VL - 9 IS - 11 N2 - Levodopa is the most effective drug for the treatment of Parkinson's disease. However, the long-term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias. Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa-induced dyskinesias, their pathogenesis is still unclear. In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements. Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias. SN - 1474-4465 UR - https://www.unboundmedicine.com/medline/citation/20880751/Levodopa_induced_dyskinesias_in_patients_with_Parkinson's_disease:_filling_the_bench_to_bedside_gap_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1474-4422(10)70218-0 DB - PRIME DP - Unbound Medicine ER -